Emerging therapeutic targets for gastric cancer from a host-Helicobacter pylori interaction perspective.
Esmat AbdiSaeid Latifi-NavidFatemeh Abedi SarvestaniMohammad Hassan EsmailnejadPublished in: Expert opinion on therapeutic targets (2021)
Wnt signaling and COX pathway have a well-documented history in the genesis of GC by HP and might be considered as the most promising targets for early GC treatment. Destroying HP may decrease the risk of GC, but it cannot fully hinder the GC development induced by HP infection. Therefore, targeting HP-activated pathways, especially COX-2/Wnt/beta-catenin/VEGF, TLR2/TLR9/COX-2, COX2-PGE2, and NF-κB/COX-2, as well as EPHA2, MMPs, and miR-543/SIRT1 axis, can be an effective measure in the early treatment of GC. However, different clinical trials and large, multi-center cohorts are required to validate these potentially effective targets for GC therapy.
Keyphrases
- helicobacter pylori
- gas chromatography
- cell proliferation
- clinical trial
- toll like receptor
- inflammatory response
- immune response
- signaling pathway
- long non coding rna
- stem cells
- endothelial cells
- vascular endothelial growth factor
- drug delivery
- replacement therapy
- long noncoding rna
- mass spectrometry
- cancer therapy
- mesenchymal stem cells
- tandem mass spectrometry